Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2025-07-03 Regulatory Filings
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
풍문또는보도에대한해명
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure from Aptamer Science regarding a market rumor or media report. It explicitly denies a specific news report about a potential acquisition. Since it is a regulatory announcement regarding market rumors and does not fit into specific categories like M&A (as it denies the activity) or financial reports, it falls under the general regulatory filing category.
2025-07-03 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Aptamer Sciences Inc., covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial data, business operations, and management analysis, which is characteristic of an interim/quarterly financial report. It is not an announcement of a report, but the report itself. Q1 2025
2025-05-15 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). It details the specific terms of the bond, the acquisition amount, the reason (exercise of put option by the bondholder), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding the company's capital structure and debt management, 'CAP' (Capital/Financing Update) is the most accurate classification.
2025-04-07 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company '압타머사이언스' (Aptamer Sciences). It details the outcomes of various agenda items such as financial statement approval, director appointments, and business purpose changes. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it reports the official results of shareholder votes at a general meeting.
2025-03-27 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory announcement regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) between Aptamer Sciences and HLB Science. It details the contract value, duration, and payment terms. Since this is a specific corporate disclosure regarding a business contract that does not fit into the other specialized categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing from Aptamer Science titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and details regarding the audit process as required by Korean regulatory standards. While it contains financial data, it is a specific notification of the audit report's submission rather than the full annual report (10-K) or a standalone audit report (AR). According to the 'Menu vs Meal' rule, this is a formal announcement of the filing of the audit report, which falls under the category of Report Publication Announcement (RPA). FY 2024
2025-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.